ClinicalTrials.gg
CompletedNCT01439815Updated Apr 14, 2021Results posted

An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo

A Phase 4 interventional study of Fluticasone Propionate Nasal Spray and Saline Nasal Spray in Allergic Rhinitis and Allergic Conjunctivitis, sponsored by ORA, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-14.

Sponsored by ORA, Inc. · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 34 studies testing fluticasone in Rhinitis, Allergic — none open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic.

Enrollment
28th of 34
22 · median 63
Started
2011
the only one that year
Phase 4
19 of 34
none open now
Registered
25th of 34
by date
Lead sponsor
2 of 34
ORA, Inc.

Among the 34 studies testing fluticasone in Rhinitis, Allergic, this one is the 28th largest by enrollment, is the only one that started in 2011, is one of 19 in phase 4, and was the 25th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

None of the 34 studies testing fluticasone in Rhinitis, Allergic is open now. The open studies under Rhinitis, Allergic, anywhere →

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies testing fluticasone in Rhinitis, Allergic as a file.
02

Study summary

The purpose of this study is to evaluate the onset of action of fluticasone propionate nasal spray compared to placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube (ABC) after up to 14 days of at home dosing.

03

Conditions studied

  • Allergic Rhinitis
  • Allergic Conjunctivitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • provide written and signed HIPAA form;
  • be able and willing to follow all instructions and attend the study visits;
  • if female and of , be not pregnant, nursing or planning a pregnancy, be willing to submit a pregnancy test at Visit 1 and at exit visit, and to use adequate method of
  • have a positive history of seasonal allergic rhinitis to ragweed;
  • have a positive skin test reaction to ragweed of within the past 24 months;
  • manifest sufficient allergic rhinitis symptoms during ragweed exposure in the ABC

Exclusion criteria

Exclusion Criteria:

  • known intolerance or allergy to antihistamines or ;
  • have a compromised lung function at Visit 1;
  • develop a compromised lung function at Visits 2-6
  • have any presence of active sinus or nasal infection at any visit;
  • have experienced an acute upper or lower respiratory tract infection or acute sinusitis within 30 days of visit 1;
  • have significant nasal anatomical deformities or any condition that does not allow subject to breathe through the nose (includes, but is not limited to: septal deviation, septal perforations, nasal polyps, rhinitis medicamentosa)
  • have had any nasal surgical intervention in the past;
  • have a known history of glaucoma
  • have planned surgery (nasal, ocular or systemic) during the trial period or within 30 days thereafter;
  • inability or refusal to discontinue contact lens wear during all visits;
  • use disallowed medications during the study or appropriate pre-study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
22 participants (actual)

Study arms

  • Placebo comparator
    Placebo Nasal Spray

    Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.

    Drug: Saline Nasal Spray

  • Active comparator
    Fluticasone Propionate

    Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.

    Drug: Fluticasone Propionate Nasal Spray

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Total Nasal Signs and Symptoms Score From Baseline (Day 0) to Visit 5 (Day 16)

    The change in the total sum of the four symptoms (total nasal symptom scores - TNSS) ranging from 0 to 16 with higher score indicating a more severe reaction. The change in the TNSS score between Day 0 and Day 16 was analyzed.

    Time frame: pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16

Secondary outcomes

  1. Change in Baseline Nasal Itching Score on Day 0 to Average Nasal Itching Score on Day 16

    Nasal Itching was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average nasal itching score between Day 0 and Day 16 was analyzed.

    Time frame: pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16

  2. Change in Baseline Sneezing Score on Day 0 to Average Sneezing Score on Day 16

    Sneezing was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average sneezing score between Day 0 and Day 16 was analyzed.

    Time frame: pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16

  3. Change in Baseline Rhinorrhea Score on Day 0 to Average Rhinorrhea Score on Day 16

    Rhinorrhea was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average rhinorrhea score between Day 0 and Day 16 was analyzed.

    Time frame: pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16

  4. Change in Baseline Nasal Congestion Score on Day 0 to Average Nasal Congestion Score on Day 16

    Nasal Congestion was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average nasal congestion score between Day 0 and Day 16 was analyzed.

    Time frame: pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16

07

Results

Posted Mar 24, 2021

Participant flow

Subjects were recruited from one site in the US.

Participant flow — Overall Study
MilestoneFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Started1111
All randomized participant population1111
Completed119
Not completed02

Outcome measures

PrimaryChange in Total Nasal Signs and Symptoms Score From Baseline (Day 0) to Visit 5 (Day 16)

The change in the total sum of the four symptoms (total nasal symptom scores - TNSS) ranging from 0 to 16 with higher score indicating a more severe reaction. The change in the TNSS score between Day 0 and Day 16 was analyzed.

Time frame:
pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16
Reported as:
Mean · units on a scale
Change in Total Nasal Signs and Symptoms Score From Baseline (Day 0) to Visit 5 (Day 16)
units on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
pre-ABC-0.7 ± 1.80.3 ± 1.8
15 minutes-2.8 ± 3.40.9 ± 3.8
30 minutes-4.1 ± 3.4-0.6 ± 3.0
45 minutes-3.9 ± 4.2-0.3 ± 3.1
60 minutes-4.7 ± 3.6-0.9 ± 3.3
75 minutes-4.5 ± 4.5-2.3 ± 3.7
90 minutes-4.5 ± 4.3-1.7 ± 3.3
105 minutes-5.0 ± 4.0-1.6 ± 2.5
120 minutes-5.9 ± 3.1-0.7 ± 3.5
135 minutes-4.8 ± 4.0-0.5 ± 3.2
150 minutes-5.3 ± 3.6-1.7 ± 2.6
165 minutes-5.4 ± 3.2-1.6 ± 2.8
180 minutes-5.9 ± 3.0-0.6 ± 3.0
SecondaryChange in Baseline Nasal Itching Score on Day 0 to Average Nasal Itching Score on Day 16

Nasal Itching was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average nasal itching score between Day 0 and Day 16 was analyzed.

Time frame:
pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16
Reported as:
Mean · units on a scale
Change in Baseline Nasal Itching Score on Day 0 to Average Nasal Itching Score on Day 16
units on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Pre-ABC-0.2 ± 0.60.1 ± 0.7
15 minutes-1 ± 10.3 ± 0.8
30 minutes-1 ± 1.2-0.1 ± 0.6
45 minutes-0.8 ± 1.6-0.1 ± 0.9
60 minutes-1.3 ± 1.3-0.3 ± 0.9
75 minutes-1.3 ± 1.5-0.5 ± 0.8
90 minutes-1 ± 1.6-0.6 ± 0.7
105 minutes-1.3 ± 1.3-0.5 ± 0.8
120 minutes-1.5 ± 1.1-0.4 ± 0.8
135 minutes-1.5 ± 1.2-0.3 ± 0.8
150 minutes-1.5 ± 1.3-0.2 ± 0.8
165 minutes-1.5 ± 1.1-0.2 ± 1
180 minutes-1.8 ± 1.20 ± 1.1
SecondaryChange in Baseline Sneezing Score on Day 0 to Average Sneezing Score on Day 16

Sneezing was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average sneezing score between Day 0 and Day 16 was analyzed.

Time frame:
pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16
Reported as:
Mean · units on a scale
Change in Baseline Sneezing Score on Day 0 to Average Sneezing Score on Day 16
units on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Pre-ABC-0.1 ± 0.30.2 ± 0.9
15 minutes-0.5 ± 1.10.1 ± 0.9
30 minutes-0.9 ± 0.8-0.4 ± 0.8
45 minutes-0.9 ± 1.10 ± 0.9
60 minutes-1.3 ± 1.1-0.2 ± 1
75 minutes-1.1 ± 1.3-0.6 ± 1.3
90 minutes-1.1 ± 1.4-0.3 ± 1.2
105 minutes-1.2 ± 1.1-0.4 ± 1
120 minutes-1.3 ± 1.3-0.1 ± 1.1
135 minutes-0.9 ± 1.40 ± 0.9
150 minutes-0.8 ± 1.3-0.7 ± 1
165 minutes-1.1 ± 0.9-0.6 ± 1
180 minutes-1.2 ± 0.8-0.1 ± 0.7
SecondaryChange in Baseline Rhinorrhea Score on Day 0 to Average Rhinorrhea Score on Day 16

Rhinorrhea was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average rhinorrhea score between Day 0 and Day 16 was analyzed.

Time frame:
pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16
Reported as:
Mean · units on a scale
Change in Baseline Rhinorrhea Score on Day 0 to Average Rhinorrhea Score on Day 16
units on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Pre-ABC-0.4 ± 0.80 ± 0.5
15 minutes-0.9 ± 0.90.4 ± 1.2
30 minutes-1.5 ± 0.80 ± 0.8
45 minutes-1.1 ± 1.1-0.2 ± 1
60 minutes-1.2 ± 1-0.1 ± 1
75 minutes-1.3 ± 1.1-0.7 ± 1.3
90 minutes-1.5 ± 1-0.5 ± 1.1
105 minutes-1.4 ± 1.4-0.5 ± 1
120 minutes-1.7 ± 0.6-0.1 ± 1
135 minutes-1.4 ± 1.10 ± 1.1
150 minutes-1.5 ± 0.8-0.4 ± 0.8
165 minutes-1.4 ± 0.8-0.4 ± 0.8
180 minutes-1.5 ± 0.9-0.3 ± 1.2
SecondaryChange in Baseline Nasal Congestion Score on Day 0 to Average Nasal Congestion Score on Day 16

Nasal Congestion was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average nasal congestion score between Day 0 and Day 16 was analyzed.

Time frame:
pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16
Reported as:
Mean · units on a scale
Change in Baseline Nasal Congestion Score on Day 0 to Average Nasal Congestion Score on Day 16
units on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Pre-ABC-0.1 ± 10 ± 0.7
15 minutes-0.4 ± 1.20.1 ± 1.3
30 minutes-0.7 ± 1.3-0.1 ± 1.2
45 minutes-1.1 ± 1.10 ± 0.9
60 minutes-1 ± 1.1-0.4 ± 0.8
75 minutes-0.9 ± 1.1-0.5 ± 1
90 minutes-1.1 ± 1.2-0.3 ± 0.9
105 minutes-1.2 ± 1-0.2 ± 0.9
120 minutes-1.5 ± 0.9-0.2 ± 0.9
135 minutes-1.1 ± 1.1-0.2 ± 0.9
150 minutes-1.4 ± 0.9-0.3 ± 0.8
165 minutes-1.4 ± 0.9-0.3 ± 0.8
180 minutes-1.5 ± 0.9-0.1 ± 0.9

Adverse events

Collected over Adverse events were collected from baseline (Day 0) through study completion (Day 16). All subjects who received study medication were evaluable for the safety analysis.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluticasone Propionate Nasal Spray0/11 (0%)0/11 (0%)1/11 (9.1%)
Placebo Nasal Spray0/11 (0%)0/11 (0%)3/11 (27.3%)
Most frequent other events
Most frequent other events
EventFluticasone Propionate Nasal SprayPlacebo Nasal Spray
hives (neck)General disorders0/111/11
dizzinessGeneral disorders1/110/11
headacheGeneral disorders0/111/11
hives (face)General disorders0/111/11

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Fluticasone Propionate Nasal SprayPlacebo Nasal SprayTotal
<=18 years000
Between 18 and 65 years111122
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Fluticasone Propionate Nasal SprayPlacebo Nasal SprayTotal
Female6612
Male5510
08

Study locations

1 site
  • Ora, Inc.
    Andover, Massachusetts 01810, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2021, 9 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2011
First posted
Sep 23, 2011
Start
Sep 2011
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Mar 24, 2021
Last update
Apr 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01439815
Lead sponsor
ORA, Inc.
Responsible party
Sponsor
First posted
Sep 23, 2011
Start date
Sep 2011
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Mar 24, 2021
Last update
Apr 14, 2021

Study contacts

Tarek Shazly, MD
principal investigator · ORA, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion